The 2025 winners of the Endpoints 11: Biotech’s most exciting startupsnews2025-09-19T14:00:57+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Umoja Biopharma hopes to break CAR-T’s in vivo barriernews2025-09-19T14:00:42+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Candid Therapeutics builds the next autoimmune powerhousenews2025-09-19T14:00:40+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Third Arc’s talented team goes after big targetsnews2025-09-19T14:00:40+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Orbis Medicines uses macrocycles to make a biologic-in-a-pillnews2025-09-19T14:00:17+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Dispatch Bio’s ambitious plans for solid tumor cell therapynews2025-09-19T14:00:15+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Sironax swings big in neurology as China biotech risesnews2025-09-19T14:00:13+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Stylus Medicine wants to bring CAR-T to the massesnews2025-09-19T14:00:11+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Judo Bio broadens the reach of RNA drugsnews2025-09-19T14:00:11+00:00September 19th, 2025|Endpoints News|
Endpoints 11 winner 2025: Averna Therapeutics wants to harness jumping genesnews2025-09-19T14:00:07+00:00September 19th, 2025|Endpoints News|
